Wellington Management Group LLP Buys 5,566 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Wellington Management Group LLP boosted its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 5.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 117,576 shares of the company’s stock after acquiring an additional 5,566 shares during the period. Wellington Management Group LLP owned 0.14% of Day One Biopharmaceuticals worth $1,443,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Laurion Capital Management LP increased its stake in shares of Day One Biopharmaceuticals by 5.4% in the 4th quarter. Laurion Capital Management LP now owns 15,000 shares of the company’s stock valued at $323,000 after purchasing an additional 763 shares during the last quarter. California State Teachers Retirement System increased its stake in shares of Day One Biopharmaceuticals by 9.5% in the 3rd quarter. California State Teachers Retirement System now owns 10,929 shares of the company’s stock valued at $219,000 after purchasing an additional 944 shares during the last quarter. Arizona State Retirement System increased its stake in shares of Day One Biopharmaceuticals by 8.8% in the 3rd quarter. Arizona State Retirement System now owns 12,363 shares of the company’s stock valued at $152,000 after purchasing an additional 995 shares during the last quarter. Parkwood LLC increased its stake in shares of Day One Biopharmaceuticals by 5.3% in the 1st quarter. Parkwood LLC now owns 20,381 shares of the company’s stock valued at $272,000 after purchasing an additional 1,028 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Day One Biopharmaceuticals by 2.4% in the 1st quarter. Rhumbline Advisers now owns 43,996 shares of the company’s stock valued at $588,000 after purchasing an additional 1,043 shares during the last quarter. Institutional investors own 87.95% of the company’s stock.

Analysts Set New Price Targets

DAWN has been the topic of several recent analyst reports. Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. Piper Sandler reiterated an “overweight” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Tuesday. Finally, The Goldman Sachs Group decreased their price target on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research note on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.60.

Day One Biopharmaceuticals Stock Up 4.6 %

NASDAQ DAWN opened at $16.52 on Friday. Day One Biopharmaceuticals, Inc. has a twelve month low of $9.67 and a twelve month high of $17.85. The company has a market cap of $1.44 billion, a price-to-earnings ratio of -6.94 and a beta of -1.48. The business’s fifty day moving average is $15.16 and its 200 day moving average is $13.54.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07). On average, research analysts anticipate that Day One Biopharmaceuticals, Inc. will post -2.66 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 2,666 shares of Day One Biopharmaceuticals stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $40,656.50. Following the transaction, the chief financial officer now directly owns 277,754 shares of the company’s stock, valued at approximately $4,235,748.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 2,666 shares of Day One Biopharmaceuticals stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $40,656.50. Following the transaction, the chief financial officer now directly owns 277,754 shares of the company’s stock, valued at approximately $4,235,748.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Samuel C. Blackman sold 2,258 shares of Day One Biopharmaceuticals stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the transaction, the insider now directly owns 1,244,662 shares in the company, valued at $18,981,095.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 45,781 shares of company stock valued at $722,960. 8.80% of the stock is currently owned by company insiders.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.